China SXT Pharmaceuticals, Inc.

China SXT Pharmaceuticals, Inc. operates in the traditional Chinese medicine pieces (TCMP) industry in China, a segment of the broader traditional Chinese medicine market that has enjoyed more rapid growth than other segments of the pharmaceutical industry primarily due to favorable government policies. The company is an innovative pharmaceutical company based in China that focuses on the research, development, manufacture, marketing and sales of TCMP, a type of Chinese Traditional Medicine product that has been widely accepted by Chinese people for thousands of years. TCMP products do not have to go through rigorous clinical trials before commercialization because of favorable government policies.

The company competes with more established companies such as Huichuntang and Tongrentang, which have greater name recognition and a larger customer base. These competitors have significantly greater financial, technical, marketing and other resources. The company's competitive advantages include being among the first to market with advanced TCMP products that can be administered orally without decoction, and the ability to sell TCMP products directly to hospitals unlike chemical entity medicines and Traditional Chinese Patent Medicine products. The company's brand is well-respected in the TCMP industry.

The company generates revenue through the manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) products. Revenue is transactional, derived from product sales to hospitals, pharmaceutical distributors, and chain pharmacies. The company sells three types of TCMP products: Advanced TCMP, Fine TCMP, and Regular TCMP, though Fine TCMP sales were discontinued during the year ended March 31, 2024. Primary customer segments include hospitals, particularly TCM hospitals, and pharmaceutical distributors, primarily in the Jiangsu province of China. The company's end-customer base as of March 31, 2026 includes 46 pharmaceutical companies, 11 chain pharmacies, and 12 hospitals across 5 provinces and municipalities.

For the fiscal year ended March 31, 2026, Advanced TCMP accounted for 4.35% ¹ of total revenue, while Regular TCMP contributed 95.02% ² of total revenue, and Other products made up the remaining 0.63% ³ of total revenue. For the fiscal year ended March 31, 2025, Advanced TCMP accounted for 14.8% ⁴ of total revenue, whereas Regular TCMP contributed 82.9% ⁵ of total revenue. For the fiscal year ended March 31, 2024, Advanced TCMP accounted for 49.1% ⁶ of total revenue, whereas Regular TCMP contributed 49.0% ⁷ of total revenue. The company has developed and introduced a diverse range of products, which include 11 ⁸ Advanced TCMPs that have been produced and marketed, 5 ⁹ Fine TCMPs, 200 ¹⁰ Regular TCMPs, and 200 ¹¹ raw medicinal materials. The Advanced TCMP products can be further divided into 7 ¹² Directly-Oral-TCMP products and 4 ¹³ After-Soaking-Oral-TCMP products. Major Directly-Oral-TCMP products include SanQiFen, CuYanHuSuo, XiaTianWu, and LuXueJing; major After-Soaking-Oral-TCMP products include ChenXiang, SuMu, ChaoSuanZaoRen, and JiangXiang. The company also previously sold Fine TCMP products, of which there were 5 ¹⁴ products, but decided to discontinue cooperation with major clients in the sales of Fine TCMP during the year ended March 31, 2024 and not to develop or sell Fine TCMP products in future.

During the fiscal year ended March 31, 2026, the company executed a securities purchase agreement on January 12, 2026, issuing 1,000,000 ¹⁵ Class A Ordinary Shares and pre-funded warrants to purchase up to 1,000,000 ¹⁶ Class A Ordinary Shares at a purchase price of $5.00 ¹⁷ per share and $4.99 ¹⁸ per pre-funded warrant, for aggregate gross proceeds of approximately $10.0 million ¹⁹. On May 5, 2025, the company entered into a securities purchase agreement for the issuance of 1,000,000 ²⁰ Class A Ordinary Shares and pre-funded warrants to purchase up to 1,000,000 ²¹ Class A Ordinary Shares at a purchase price of $5.00 ²² per share and $4.99 ²³ per pre-funded warrant, for aggregate gross proceeds of approximately $10.0 million ²⁴. On February 25, 2025, the company effectuated a one-for-eight (1:8) reverse split for its ordinary shares. On July 28, 2025, shareholders approved an amended and restated memorandum and articles of association to create a new class of Class B Ordinary Shares, re-designating 532 ²⁵ Ordinary Shares held by Feng Zhou Management Limited into 532 ²⁶ Class B Ordinary Shares, and re-designating the remaining then issued 116,027,226 ²⁷ Ordinary Shares as 116,027,226 ²⁸ Class A Ordinary Shares with no par value each. On February 3, 2026, the company adopted the 2025 Equity Incentive Plan, under which 1,000,000 ²⁹ Class A Ordinary Shares were initially reserved for issuance. On April 30, 2025, the company granted 1,000,000 ³⁰ restricted stock units to employees under the 2025 Equity Incentive Plan. On May 16, 2025, the company issued 1,000,000 ³¹ Class A Ordinary Shares and pre-funded warrants to purchase up to 1,000,000 ³² Class A Ordinary Shares at a purchase price of $5.00 ³³ per share and $4.99 ³⁴ per pre-funded warrant, for aggregate gross proceeds of approximately $10.0 million ³⁵.

Total revenues decreased from $1,740,907 ³⁶ in the fiscal year ended March 31, 2025 to $1,138,052 ³⁷ in the fiscal year ended March 31, 2026, representing a decrease of 35% ³⁸. Net loss increased from $3,030,652 ³⁹ in fiscal 2025 to $6,205,085 ⁴⁰ in fiscal 2026, representing an increase of 88% ⁴¹ of net loss. Total revenues decreased from $1,928,497 ⁴² in the fiscal year ended March 31, 2024 to $1,740,907 ⁴³ in fiscal 2025, representing a decrease of 10% ⁴⁴. Net loss increased from $3,098,532 ⁴⁵ in fiscal 2024 to $3,030,652 ⁴⁶ in fiscal 2025, representing an increase of 7% ⁴⁷ of net loss. As of March 31, 2026, the company had cash and cash equivalents and restricted cash of $28,176,233 ⁴⁸, total current assets of $34,509,722 ⁴⁹, and total current liabilities of $4,349,320 ⁵⁰. As of March 31, 2025, the company had cash and cash equivalents and restricted cash of $18,129,432 ⁵¹, total current assets of $21,296,491 ⁵², and total current liabilities of $6,012,063 ⁵³.

The company plans to increase its efforts in cooperation with universities, research institutes, and R&D agents on joint R&D projects involving TCMP processing methods and quality standard, as well as the training of its researchers. The company's general R&D strategy was established to use advanced technology to revolutionize TCMP production and continue developing newly advanced and non-decocting TCMP/TCM products capable of meeting the highest quality standard. The strategy includes a calculated system of studying aqueous extracting ratio and fingerprint or characteristic charts of components, quantization of bioactive compounds, quality control, stability, development of production process of TCMP products, and establishing a higher benchmark for advanced TCMP products in China.

The company's growth strategy also involves expanding its customer base. As of March 31, 2026, the company's end-customer base includes 46 ⁵⁴ pharmaceutical companies, 11 ⁵⁵ chain pharmacies and 12 ⁵⁶ hospitals in 5 ⁵⁷ provinces and municipalities in China including Jiangsu, Anhui, Jiangxi, Guangdong and Hubei. The company currently has 4 ⁵⁸ sales offices covering 12 ⁵⁹ of China's major provinces/municipalities, including Jiangsu, Hubei, Shandong, Liaoning, Anhui, Henan, Jiangxi, Guangdong, Chongqing, Sichuan, Hebei and Fujian, and over 68 ⁶⁰ sales representatives who assist in managing relationships with existing distributors and developing future distributors.The filing does not contain a specific operational outlook for supply chain, manufacturing capacity, technology infrastructure investments, or headcount strategy for the upcoming period.

The filing does not contain specific R&D spending levels, capital expenditure plans, share repurchase authorization amounts, or dividend policy figures for the upcoming period.

The company faces significant customer concentration risk. Suxuantang had one significant customer which accounted for 86.95% ⁶¹ of total revenue during the year ended March 31, 2026, and one significant customer which accounted for 68.72% ⁶² of total revenue during the year ended March 31, 2025. The company expects that Suxuantang's largest customers will continue to account for a substantial portion of its total net revenue for the foreseeable future. The company also faces risks related to the need for substantial additional financing, as it will need to engage in capital-raising transactions in the near future.

The company operates in a highly regulated industry in China and faces risks from price control regulations. The prices of certain TCMP products the company distributes, including those listed in the Insurance Catalogue, are subject to control by the relevant state or provincial price administration authorities. Since May 1998, the relevant PRC governmental authorities have ordered price reductions on thousands of pharmaceutical products. The company also faces risks from potential changes to the Insurance Catalogue, as 95% ⁶³ of its TCMP products, including 18 ⁶⁴ Advanced TCMP products, are currently listed in the insurance catalogue.

The company faces significant customer concentration risk, as one customer accounted for 86.95% ⁶⁵ of total revenue during the year ended March 31, 2026, and one customer accounted for 68.72% ⁶⁶ of total revenue during the year ended March 31, 2025. The company has limited sources of working capital and will need substantial additional financing, with cash and cash equivalents and restricted cash of $28,176,233 ⁶⁷ as of March 31, 2026. The company's TCMP business is subject to price control regulations in the PRC, and since May 1998, the relevant PRC governmental authorities have ordered price reductions on thousands of pharmaceutical products. Additionally, 95% ⁶⁸ of the company's TCMP products, including 18 ⁶⁹ Advanced TCMP products, are listed in the insurance catalogue, and removal from this catalogue could materially reduce revenue. The company also relies on VIE Agreements with Taizhou Suxuantang for its business operations, and these contractual arrangements have not been tested in a court of law in China, creating uncertainty regarding their enforceability.

Management's message in the filing emphasizes the company's position as an innovative pharmaceutical company focusing on the research, development, manufacture, marketing and sales of TCMP, and highlights the favorable government policies for the TCMP industry that have allowed it to enjoy more rapid growth than other segments of the pharmaceutical industry. The filing notes that the company's revenues decreased from $1,740,907 ⁷⁰ in fiscal 2025 to $1,138,052 ⁷¹ in fiscal 2026, a decrease of 35% ⁷², and net loss increased from $3,030,652 ⁷³ to $6,205,085 ⁷⁴, an increase of 88% ⁷⁵. Management emphasizes the company's innovative features of its Advanced TCMP products, which can be administered orally without decoction, and the company's competitive edge in the market. The strategic priorities emphasized include continuing to develop newly advanced and non-decocting TCMP/TCM products, increasing cooperation with universities and research institutes on joint R&D projects, and expanding the customer base through the company's 4 ⁷⁶ sales offices and over 68 ⁷⁷ sales representatives.